As demonstrated in Figure 2, in all three models, the combination of CBDCA and anti-PD-1 antibodies reduced the tumor size at the early phase after implantation (CBDCA+α-PD-1 vs. CTRL, p < 0.0001) and prolonged the survival of tumor-bearing mice (CBDCA+α-PD-1 vs. CTRL, p < 0.0001 in 4T1 and E0771 tumors, and p < 0.001 in EMT6 tumor). Here, PDCD1 is linked to neoplasm.